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Sebaceous gland carcinoma (SGC) is a rare, but life-threatening condition with a predilection for the 
periocular region. Eyelid SGC can be broadly categorised into two subtypes, namely either nodular 
or pagetoid with the latter being more aggressive and requiring radical excision to save life. We have 
identified key altered microRNAs (miRNA) involved in SGC shared by both subtypes, hsa-miR-34a-5p 
and hsa-miR-16-5p. However, their gene targets BCL2 and MYC were differentially expressed with both 
overexpressed in pagetoid but unchanged in nodular suggesting different modes of action of these two 
miRNAs on BCL/MYC expression. Hsa-miR-150p is nodular-specifically overexpressed, and its target 
ZEB1 was significantly downregulated in nodular SGC suggesting a tumour suppressor role. Invasive 
pagetoid subtype demonstrated specific overexpression of hsa-miR-205 and downregulation of hsa-
miR-199a. Correspondingly, miRNA gene targets, EZH2 (by hsa-miR-205) and CD44 (by hsa-miR-199a), 
were both overexpressed in pagetoid SGC. CD44 has been identified as a potential cancer stem cell 
marker in head and neck squamous cell carcinoma and its overexpression in pagetoid cells represents 
a novel treatment target. Aberrant miRNAs and their gene targets have been identified in both SGC 
subtypes, paving the way for better molecular understanding of these tumours and identifying new 
treatment targets.
Sebaceous gland carcinoma (SGC) is a rare, aggressive cancer that has a predilection for the periorbital region, 
perhaps due to the multitude of glands surrounding the globe, but can come from extraocular sites, albeit mainly 
within the head region1. Geographical variation is significant with the incidence around 0.65 per 100,000 in 
Canada versus China where it represents almost a third of the malignant eyelid workload and second to BCC 
in frequency2,3. In Japan, the rate of SGC equalled that of BCC in one study4. Risk factors for developing SGC 
include radiation exposure; for example external beam radiotherapy which used to be the mainstay of treatment 
for retinoblastoma5. More aggressive features include vascular and lymphatic invasion, orbital invasion, involve-
ment of both upper and lower eyelids, poor differentiation, multicentric origin, diameter greater than 10 mm, 
infiltrative growth pattern and pagetoid invasion of the adjacent epithelium6. SGC can be broadly divided in to 
two subtypes with highly contrasting prognosis, namely: nodular and pagetoid7. The nodular form often presents 
as a discrete mass on the eyelid and is more amenable to curative surgical resection whereas the pagetoid (intraep-
itheial spread on histology) subtype presents as non-specific thickening or redness of the eye and often contains 
skip lesions that requires more mutilating surgery to achieve complete clearance8. Surgical excision is currently 
the only available treatment and this may require removal of a normal seeing eye (exenteration) to protect life, 
thus a better understanding of its molecular biology along with identification of alternative treatment modalities 
is needed9,10.
Little is known about the molecular factors involved in SGC tumorigenesis although recent targeted whole 
exome sequencing of periocular SGC has revealed mutations in TP53 and RB1 genes11. Four differentially 
expressed microRNA (miRNA) have been identified in SGC (hsa-miR-486-5p and -184 upregulated; hsa-miR-211 
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and -518d downregulated), however, these miRNAs were compared to sebaceous adenoma rather than normal 
tissue and no histological subtype analysis was made12. Furthermore, progression from sebaceous adenoma to 
carcinoma is unknown, unlike the transition from colonic adenoma to adenocarcinoma, confounding the discov-
ery of real SGC tumorigenesis markers.
SGC prognosis is dependent on the subtype, with pagetoid conferring a poorer prognosis and nodular a better 
prognosis8. In this study we assess periocular SGC whole-miRNA profile normalised to eyelid tarsal plate, the 
presumed tissue of origin. We have identified aberrantly expressed miRNAs unique to pagetoid and nodular SGC 
along with shared aberrant miRNAs. Subsequently, a combination of in-silico miRNA target search and tran-
scriptome profiling, as well as miRNA-target gene network analysis, was performed to highlight miRNA targets 
in both subtypes.
Results and Discussion
Sebaceous gland carcinoma is a rare, but aggressive cancer with surgical excision as the only option for definitive 
treatment. In order to carry out complete excision a margin of normal tissue needs to be removed and verified 
using histological examination. Certain subtypes of SGC present with a local mass, termed nodular SGC and is 
more amenable to local resection (see Supplementary Fig. S1A and S1C), as a result confer a better prognosis. In 
contrast, diffuse lid swelling which demonstrates intraepithelial spread on histological and sometimes skip lesions 
do not demonstrate clear margins for wide local excision, thus more aggressive excision of the orbital content is 
required resulting in a poorer prognosis (see Supplementary Fig. S1B and S1D). However, little is known about 
the molecular biology of these tumours and the relationship between SGC miRNA profile, transcriptome and its 
cancer behaviour including the differences exhibited by the nodular and pagetoid subtypes.
Common SGC miRNA in both nodular and pagetoid subtype with target gene expression. 
Thirty-nine differentially expressed (DE) miRNA were common to both subtypes with the majority being upreg-
ulated (Fig. 1A). The top 4 DE miRNAs are shown in Fig. 1B (see Supplementary Table S1).
Hsa-miR-34a was significantly overexpressed in both subtypes compared to the control (Fig. 1B,C). It forms 
part of the TP53 suppressor network by modulating TP53 targets and forms a positive feedback loop via SIRT113. 
Despite the common overexpression of hsa-miR-34a in both subtypes, the action of the miRNA on its target 
gene is different. For example, the target gene MYC was significantly overexpressed in the pagetoid subtype, but 
remaining unchanged in nodular (Fig. 1D). Interestingly in MYC-driven tumours, hsa-miR-34a improves cell 
survival based on its ability to reduce TP53 levels, in a MYC mediated and dependent fashion, hence helps the 
Figure 1. Shared microRNAs in nodular and pagetoid sebaceous gland carcinoma (SGC). (A) Thirty-nine 
significant differentially expressed microRNA shared between both subtypes using a p < 0.05 threshold.  
(B) Top 4 differentially expressed miRNAs present in both nodular and pagetoid SGC when compared to tarsal 
plate control. (C) MicroRNA verification of expression using Taqman RT-qPCR in SGC. Relative expression 
levels were determined for nodular and pagetoid SGC using Taqman RT-qPCR against normal eyelid tissue 
for miRNA (i) 34a-5p and (ii) 16-5p. (D) Expression of target genes in both nodular and pagetoid subtypes. 
Significance levels are shown as *P < 0.05, **P < 0.01, ***P < 0.001. Error bars represent mean +/− s.d.
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cancer cells to survive14. As MYC is over-expressed in the pagetoid subtype, our results suggest that hsa-miR-
34a may play a tumour activating and enhancing role, but not the case in nodular SGC where the expression of 
MYC was unchanged compared to normal control (Fig. 1D). Furthermore, there is a known synergistic action 
between BCL2, also a target of hsa-miR-34a, and MYC in oncogenesis and this appears to be occurring in the 
pagetoid form only where both were significantly overexpressed (Fig. 1D)15. Hsa-miR-16 also targets BCL2 and 
was similarly overexpressed in both subtypes (Fig. 1B,C). Moreover, hsa-miR-16 has been shown to suppress both 
BCL2 and FOXO1, the latter being under-expressed in nodular SGC only16. It may therefore be acting in a similar 
opposing fashion as hsa-miR-34 and behave with a different mode of action according to the MYC and BCL2 sta-
tus of the two subtypes. Hsa-mir-9, a known tumour suppressor, is overexpressed in both subtypes, and together 
with hsa-miR-619 (downregulated in both subtypes), targets MDGA2, a tumour suppressor gene which is high-
lighted in our common SGC miRNA-target gene network shown in Supplementary Fig. S217,18. Both hsa-miR-126 
and -9 target chemokine receptor CXCR4 which plays a role in metastatic spread19,20.
Nodular SGC specific microRNA with target gene expression. Seventy-five DE genes were found to 
be unique to nodular SGC compared to control and pagetoid (Fig. 2A). The majority of these (63%) were down-
regulated and the top 3 nodular specific miRNA are shown in Fig. 2B (see Supplementary Table S1).
Hsa-miR-150 was the most overexpressed miRNA unique to nodular SGC, with more than an 8-fold change 
(Fig. 2B,C) compared to control. Tumour suppressor action of hsa-miR-150 has been noted in epithelial ovarian 
cancer and shown to reduce invasion and metastasis by suppressing the transcriptional repressor ZEB1 which 
was significantly downregulated in nodular SGC (Fig. 2D)21. Hsa-miR-143 was also found significantly upreg-
ulated specifically to the nodular subtype (Fig. 2B) and known for its tumour suppressive action22. It is likely 
to be acting through suppression of BCL2, which is also targeted by the aforementioned hsa-miR-16 and -34a, 
helping to prevent cancer progression. In contrast, BCL2 is significantly overexpressed in the pagetoid subtype 
and as an important inhibitor of apoptosis, confers an advantage to the pagetoid subtype, however, BCL2 also 
represents a potential novel treatment target.23 Oncomir hsa-miR-603 was found to be much more downreg-
ulated in nodular than in pagetoid subtype (Fig. 2B) and we propose it is attempting to regulate of E2F1 in a 
negatively correlated fashion which may contribute to nodular SGC less aggressive behaviour (Supplementary 
Fig. S3)24,25. A miRNA-target gene network of the proposed regulatory interactions seen in nodular SGC is shown 
in Supplementary Fig. S3. The MAPK/ERK pathway is intimately linked to the altered miRNAs seen in nodular 
SGC and it is possible that these miRNAs are acting as tumour suppressors to inhibit this pathway26,27. Moreover, 
Figure 2. Nodular sebaceous gland carcinoma specific microRNAs. (A) Seventy-five significant differentially 
expressed microRNA unique to nodular SGC using a p < 0.05 threshold. (B) Top 3 differentially expressed 
miRNAs present in nodular SGC only when compared to tarsal plate control. Pagetoid expression shown to 
demonstrate non-significant change within the subtype. (C) MicroRNA verification of 150-5p expression using 
Taqman RT-qPCR in SGC. Relative expression levels were determined for nodular and pagetoid SGC using 
Taqman RT-qPCR against normal eyelid tissue for miRNA 150-5p. (D) Expression of target genes in nodular 
and pagetoid subtype for hsa-miR-150-5p. Significance levels are shown as *P < 0.05, **P < 0.01, ***P < 0.001. 
Error bars represent mean +/− s.d.
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synthetic miR-143 has been shown to silence KRAS signalling including its effector signalling molecules AKT and 
ERK (MAPK1).28 Furthermore, high expression of hsa-miR-150 specifically occurs in cancer patients and has the 
potential to be a biomarker of disease29.
Pagetoid specific microRNA with target gene expression. Pagetoid SGC expressed 53 specific, sig-
nificantly DE genes (Fig. 3A). 47% of them were downregulated and the top 3 pagetoid specific genes are shown 
in Fig. 3B (see Supplementary Table S1).
Significantly increased level of hsa-miR-205 was found to be unique to pagetoid SGC and overexpression 
promotes VEGF invasion of ovarian cancer cells by targeting EZR and LMNA (Fig. 3B,C)30. Higher levels of 
hsa-miR-205 are also associated with adverse clinical outcome in bladder and biliary cancer through its action 
on ZEB1 by maintaining an epithelial phenotype31,32. Upregulation of hsa-miR-205 also occurs in non-squamous 
cell lung cancer and directly represses PTEN (targeted by multiple pagetoid specific differentially expressed miR-
NAs, including hsa-miR-205 and hsa-miR-200a – see Supplementary Fig. S4) and PHLPP2 expression, which 
in turn activates the AKT/FOXO3a and AKT/mTOR pathways respectively33. Moreover, an interaction between 
hsa-miR-205 and overexpressed EZH2 occurs in renal cell carcinoma to control b-catenin, and indeed EZH2 was 
found to be significantly overexpressed in pagetoid SGC (Fig. 3D)34.
Hsa-miR-200a, also a pagetoid specific upregulated miRNA, is involved in EMT too, but works together with 
hsa-miR-141 (upregulated in pagetoid only) to target MAPK14 to enhance the oxidative stress tumour growth 
response in ovarian cancer and effectively behaving as oncomiRs (Fig. 3B and see Supplementary Fig. S4).35
Hsa-miR-199 acts as a tumour suppressor gene in several cancers including colorectal and thyroid cancer36,37. 
Indeed, it was found to be the most downregulated miRNA unique to pagetoid SGC (Fig. 3B,C). Hsa-miR-199 has 
been shown to target CD44 glycoprotein, an oncoprotein that aids in cell adhesion and migration, with increased 
CD44 expression contributing to the aggressive nature of tumours and represents a therapeutic target plus possi-
ble stem cell biomarker38,39. This inverse association has also been noted in hepatocellular carcinoma40. CD44 was 
found to be significantly overexpressed in pagetoid subtype, which supports the suppressing role of hsa-miR-199 
on CD44 seen in this subtype (Fig. 3). A summary of a pagetoid SGC specific miRNA-target gene network is 
shown in Supplementary Fig. S4, with common aforementioned gene targets highlighted along with the p53 
feedback pathway (MAPK and PTEN).
Figure 3. Pagetoid sebaceous gland carcinoma specific microRNAs. (A) Fifty-three significant differentially 
expressed microRNAs unique to nodular SGC using a p < 0.05 threshold. (B) Top 3 differentially expressed 
genes present in pagetoid SGC only when compared to tarsal plate. Nodular expression shown to demonstrate 
non-significant change within the subtype. (C) MicroRNA expression using Taqman RT-qPCR in SGC. Relative 
expression levels were determined for nodular and pagetoid SGC using Taqman RT-qPCR against normal eyelid 
tissue for miRNA (i) 199a-3p, (ii) 205-5p. (D) Expression of target genes in nodular and pagetoid subtype for 
hsa-miR-199a-3p and hsa-miR-205-5p. Significance levels are shown as *P < 0.05, **P < 0.01, ***P < 0.001. 
Error bars represent mean +/− s.d.
www.nature.com/scientificreports/
5SCIenTIfIC RepORTS |  (2018) 8:7531  | DOI:10.1038/s41598-018-25900-z
MiRNA-target gene networks and integrative analysis of sebaceous gland carcinoma. Integrative 
genomic analysis has been shown to be a powerful tool in identifying cancer subtype-specific highly connected 
network genes and signatures, which could offer potential subtype-specific drug targets41–43. These kind of studies 
often benefit from the availability of multi-omics data sets, especially on the same patient samples, such as TCGA 
studies: for example, in ovary44, lung45 and oesophageal46. The integration of different types of molecular data along 
with known human signalling plus protein-protein interaction, miRNA-target gene networks can further point us 
to a set of genes or pathways frequently targeted by various types of alterations and the interplay between them. To 
further identify robust SGC subtype specific signatures, we will need to generate and curate more multi-omic data 
sets (such as whole exome sequencing, RNA sequencing, copy number aberration and methylation), however SGC 
samples are rare to obtain, making it difficult to generate such datasets. More genomic studies involving multiple 
national and international centres are therefore much desired.
Development of computational models for SGC related miRNA prediction. To further validate 
the functional significance and disease causal potential for our identified shared and specific miRNAs, curated, 
known miRNA-disease associations were queried for these miRNAs using HMDD v2.047, MiRCancer48 and 
MiR2Disease49. These databases collect and record miRNA-disease associations through text mining in literature, 
manual confirmation, and experimentally supported evidence. Out of all 167 significantly differentially expressed 
miRNAs in SGC compared to control, ~100 (60%) were reported to be associated with at least one human disease 
with experiment-supported evidence based on HMDDv2.0. Similar percentages of miRNAs were also reported 
to have human disease and/or cancer associations based on MiRCancer and MiR2Disease, 60% and 48%, respec-
tively. Thus, more than half of our SGC related miRNAs have been approved experimentally to be involved in 
other diseases and cancers.
Currently, there are little known, validated or predicted associations between miRNAs and SGC. Thus, it 
would be interesting to develop a computational framework for their association prediction, in addition to our 
Nanostring experimental data. This framework often requires first the prediction of miRNA functional simi-
larity, disease semantic similarity, and the validated miRNA-disease associations. Similarity matrices are then 
integrated with Gaussian kernel similarity to produce the integrated similarity matrices for both miRNAs and 
diseases. Based on the assumption that functionally similar miRNAs tend to be associated with similar diseases, 
we can then identity and prioritise potential miRNA-SGC associations using graph-based learning (such as 
LRSSLMDA50 and PBMDA51), singular value thresholding algorithm (for example MCMDA52), or a within and 
between score model (for example WBSMDA53). Nevertheless, more studies are still needed to understand this 
rare and aggressive disease to improve the disease similarity prediction within this computational framework.
Conclusion
We have identified novel aberrant miRNAs in SGC and related them to specific subtypes of SGC with differ-
ent tumour behaviour to infer their role in carcinogenesis. Concomitantly, we assessed the transcriptome to 
explore the differential expression of predicted key target genes by these aberrant miRNAs, with the integration 
of miRNA-target gene networks associated with SGC and its subtypes. Further work is needed to understand the 
interplay of these novel miRNA in SGC tumour progression and their potential as treatment targets in the future.
Methods
Patients and tumours. This study included eight SGC samples from archival tissue housed at Moorfields 
Biobank and obtained both institutional (local) review board approval and national research ethics commit-
tee approval: Moorfields Eye Hospital Biobank internal research ethics committee agreement (reference: 10/
H0106/57-2012ETR28), sponsor approval by Queen Mary University of London (number: 008621GM) and 
overall approval from the heath research authority, national research ethics service, Committee North West - 
Greater Manchester South (national research ethics committee number 14/NW/1080). As a result, all methods 
were carried out in accordance with relevant guidelines and regulations. In addition, all experimental protocols 
were approved by the aforementioned institutional and national ethical licensing committees. Four samples were 
pagetoid, 4 were nodular and compared to 4 normal tarsal plate as controls (see Supplementary Table S2). Six 
SGC were analysed for miRNA and 8 for messenger (mRNA) whilst being compared to tarsal plate control. 
Informed consent was taken for each patient for study publication and publication of identifying images in an 
online open access publication.
Micro and messenger RNA extraction. RNeasy® FFPE kit from Qiagen® was used to extract both mes-
senger and microRNA.
A Qubit® 2.0 Fluorometer (invitrogen™ by Life technologies™) and an Agilent 2100 bioanalyzer instrument 
(Agilent technologies, Inc) was used to determine concentration and integrity of messenger RNA (mRNA).
Nanostring® nCounter®v2 microRNA expression assay and bioinformatics pipeline. Hybridisation 
of 800 unique oligonucleotide miRNA tags based on the miRBase version 18 reaction was performed. Raw miRNA 
expression and normalised data were first generated from Nanostring nCounter Digital Analyzer. Filtered data from 
the Nanostring platform were log2 transformed and further normalised using the quantile normalisation method in 
R (http://www.r-project.org/). Differential expression (DE) analyses were performed using the limma R package54. 
Pairwise comparisons of nodular versus control and pagetoid versus control were conducted to identify common and 
unique DE miRNA to the two subtypes using p < 0.05 (see Supplementary Table S1).
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Affymetrix™GeneChip® Human Gene 2.0 messenger RNA expression array and pipeline. 
Twelve samples were analysed (4 pagetoid, 4 nodular and 4 control) covering 47,000 transcripts. Expression 
data was normalised using the GC-robust multiarray average55. DE genes were identified using the threshold of 
p < 0.01 with limma R (see Supplementary Table S1). Data has been deposited to the Gene Expression Omnibus 
under the accession of GSE101476 (www.ncbi.nlm.nih.gov/geo).
Real-time quantitative reverse transcriptase–PCR (rt-qPCR) for microRNA validation. A library 
of cDNA from isolated miRNA was made using TaqMan® Advanced miRNA cDNA synthesis kit. Customised 
oligonucleotides for micoRNA were designed (see Supplementary Table S3) and hsa-miR-26a-5p was chosen as 
the control (see Supplementary Table S4). A minimum of three replicates for each reaction and relative transcript 
expression was calculated by the 2−ΔΔCt method and miRNA levels of each gene were normalised to the geometric 
mean of hsa-miR-26a-5p.
In silico miRNA-target gene network. For selected top differentially expressed miRNAs, their tar-
geted genes were identified in silico using miRNA target prediction databases (www.mirbase.org; www.mirdb.
org; www.mirtarbase.mbc.nctu.edu.tw)56–58. The differential expression patterns of these target genes were then 
explored based on our mRNA expression data. The miRNA-target gene networks were further constructed using 
Cytoscape v3.3.0 (http://www.cytoscape.org/), with various shapes and colours indicating different attributes of 
miRNAs and genes.
Accession codes. Data has been deposited to the Gene Expression Omnibus under the accession of GSE101476 
(www.ncbi.nlm.nih.gov/geo).
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